Abstract
Background Human respiratory syncytial virus (HRSV) is a common cause of lower respiratory tract infections globally. Newly-licensed prophylactic vaccines and monoclonal antibodies are anticipated to alleviate this burden; however, such interventions may exert selective pressures on HRSV evolution.
Methods Whole-genome sequencing was performed on HRSV-A (n=123) and -B (n=110) samples collected during three HRSV seasons in the 2021-2024 period from community cases. Additionally, G gene sequences, HRSV-A (n=141) and -B (n=141), collected in the 2015-2019 period were examined. Lineages were assigned by phylogenetic analyses including reference lineages.
Results Phylogenetic trees inferred with the G gene and whole genomes were consistent. Changes in the prevalence of certain lineages post-COVID-19 reflected the impact of non-pharmaceutical interventions introduced to reduce SARS-CoV-2 transmission. The HRSV-A lineages A.D.1 and A.D.5 were dominant, while B.D.E.1 was the dominant lineage for HRSV-B. Similar trends were also observed in prevalent lineages in the European region. The emergence of a new lineage was identified as descended from A.D.1 with eight distinctive substitutions in proteins G, F and L. Other circulating lineages with amino acid substitutions were observed in the F glycoprotein which could impact binding sites of nirsevimab.
Conclusion We provide the first comprehensive analysis of HRSV transmission and evolution in Ireland over the last decade through the selective forces created by the measures introduced during the COVID-19 pandemic. This study provides a foundation for future public health surveillance employing pathogen genomics to enable an evidence-based assessment of the impact of pharmaceutical interventions on HRSV evolution and disease severity.
What did you want to address in this study and why?We aimed to address conditions enabling the yearly increase in the number of HRSV cases in recent years and the viral genetic diversity. A whole-genome sequencing-based molecular epidemiology of HRSV will be key to monitoring the effectiveness and impact of new immunisation programmes in the coming years.
What have we learnt from this study?We have established a genomic-epidemiological baseline for HRSV in Ireland, and demonstrated a significant change in the diversity and abundance of viral lineages in circulation before, and after, the early years of the COVID-19 pandemic. Such changes in the most prevalent HRSV genetic lineages were shown to follow a similar trend across Europe during this time.
What are the implications of your findings for public health?The characterised viral genetic diversity represents a benchmark for evidence-based future assessments of the effectiveness and the impact of new pharmaceutical interventions in Ireland i.e. monoclonal antibodies and HRSV vaccines for paediatric, geriatric and immunocompromised cohorts. Such preventive options are anticipated to reduce the HRSV burden to public health and better protect the populations at risk.
Competing Interest Statement
DH has previously received a speaker-fee from Sanofi unrelated to this work.
Funding Statement
The institutions of the following co-authors are partners in Preparing for RSV Immunization and Surveillance in Europe (PROMISE); LP, LA, HV, AM (RIVM). This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034339. This Joint Undertaking receives support from the European Union - Horizon 2020 research and innovation programme and EFPIA. This study was partially supported by AMED under the grant number JP223fa627005.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study analyses publicly available data collected during the surveillance and report of HRSV in Ireland. The collection analysis of this data was reviewed by the Human Research Ethics Committee Sciences of the University College Dublin with the reference number LS-LR-23-226-Carr.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript or is part of the supplementary data available online: https://doi.org/10.5281/zenodo.12797565
